[go: up one dir, main page]

WO2020065409A8 - Molécules de liaison anti-cd40 ayant des domaines fc modifiés et leurs utilisations thérapeutiques - Google Patents

Molécules de liaison anti-cd40 ayant des domaines fc modifiés et leurs utilisations thérapeutiques Download PDF

Info

Publication number
WO2020065409A8
WO2020065409A8 PCT/IB2019/001135 IB2019001135W WO2020065409A8 WO 2020065409 A8 WO2020065409 A8 WO 2020065409A8 IB 2019001135 W IB2019001135 W IB 2019001135W WO 2020065409 A8 WO2020065409 A8 WO 2020065409A8
Authority
WO
WIPO (PCT)
Prior art keywords
binding molecules
engineered
domains
therapeutic uses
igg2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2019/001135
Other languages
English (en)
Other versions
WO2020065409A3 (fr
WO2020065409A2 (fr
Inventor
Yi Wu
Jieyi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lyvgen Biopharma Suzhou Co Ltd
Lyvgen Biopharma Co Ltd
Original Assignee
Lyvgen Biopharma Suzhou Co Ltd
Lyvgen Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201980064218.4A priority Critical patent/CN112996818B/zh
Priority to CN202210955817.9A priority patent/CN116178544A/zh
Priority to AU2019349874A priority patent/AU2019349874A1/en
Priority to EP19867441.8A priority patent/EP3856790A4/fr
Priority to CN202210957160.XA priority patent/CN116063495A/zh
Priority to KR1020217012243A priority patent/KR20210070317A/ko
Priority to JP2021517801A priority patent/JP7626698B2/ja
Application filed by Lyvgen Biopharma Suzhou Co Ltd, Lyvgen Biopharma Co Ltd filed Critical Lyvgen Biopharma Suzhou Co Ltd
Priority to CA3114567A priority patent/CA3114567A1/fr
Publication of WO2020065409A2 publication Critical patent/WO2020065409A2/fr
Publication of WO2020065409A3 publication Critical patent/WO2020065409A3/fr
Priority to US17/206,685 priority patent/US11186648B2/en
Anticipated expiration legal-status Critical
Publication of WO2020065409A8 publication Critical patent/WO2020065409A8/fr
Priority to US17/536,974 priority patent/US20220081487A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des molécules de liaison à CD40 comprenant des domaines IgG humains modifiés, par exemple, des variants IgG1, IgG2 et IgG4 humains ayant des mutations dans le domaine charnière, qui présentent une activité de liaison modifiée à un ou plusieurs récepteurs Fey. L'invention concerne également des procédés pour activer ou inhiber sélectivement des réponses immunitaires chez un sujet à l'aide des molécules de liaison à CD40.
PCT/IB2019/001135 2018-09-28 2019-09-27 Molécules de liaison anti-cd40 ayant des domaines fc modifiés et leurs utilisations thérapeutiques Ceased WO2020065409A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020217012243A KR20210070317A (ko) 2018-09-28 2019-09-27 조작된 Fc 도메인을 갖는 항-CD40 결합 분자 및 그의 치료적 용도
CN202210955817.9A CN116178544A (zh) 2018-09-28 2019-09-27 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
AU2019349874A AU2019349874A1 (en) 2018-09-28 2019-09-27 Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof
EP19867441.8A EP3856790A4 (fr) 2018-09-28 2019-09-27 Molécules de liaison anti-cd40 ayant des domaines fc modifiés et leurs utilisations thérapeutiques
CN202210957160.XA CN116063495A (zh) 2018-09-28 2019-09-27 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
JP2021517801A JP7626698B2 (ja) 2018-09-28 2019-09-27 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
CA3114567A CA3114567A1 (fr) 2018-09-28 2019-09-27 Molecules de liaison anti-cd40 ayant des domaines fc modifies et leurs utilisations therapeutiques
CN201980064218.4A CN112996818B (zh) 2018-09-28 2019-09-27 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
US17/206,685 US11186648B2 (en) 2018-09-28 2021-03-19 Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereof
US17/536,974 US20220081487A1 (en) 2018-09-28 2021-11-29 Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018010828 2018-09-28
CNPCT/CN2018/108285 2018-09-28
CNPCT/CN2018/010828 2018-09-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/206,685 Continuation US11186648B2 (en) 2018-09-28 2021-03-19 Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereof

Publications (3)

Publication Number Publication Date
WO2020065409A2 WO2020065409A2 (fr) 2020-04-02
WO2020065409A3 WO2020065409A3 (fr) 2020-05-07
WO2020065409A8 true WO2020065409A8 (fr) 2021-06-17

Family

ID=69950020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/001135 Ceased WO2020065409A2 (fr) 2018-09-28 2019-09-27 Molécules de liaison anti-cd40 ayant des domaines fc modifiés et leurs utilisations thérapeutiques

Country Status (4)

Country Link
JP (1) JP7626698B2 (fr)
AU (1) AU2019349874A1 (fr)
CA (1) CA3114567A1 (fr)
WO (1) WO2020065409A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019255781A1 (en) 2018-04-20 2020-10-29 Lyvgen Biopharma Holdings Limited Anti-CD40 antibodies and uses thereof
KR20230042596A (ko) * 2020-08-07 2023-03-28 제넨테크, 인크. Flt3 리간드 융합 단백질 및 이용 방법
WO2022133543A1 (fr) * 2020-12-23 2022-06-30 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Immunoglobuline modifiée ayant une affinité pour fcgammariib et son procédé d'utilisation
WO2024126294A1 (fr) * 2022-12-13 2024-06-20 Evotec International Gmbh Protéines de liaison à l'antigène associées à l'interféron destinées à être utilisées pour le traitement ou la prévention d'une infection au virus parainfluenza
WO2024126289A1 (fr) * 2022-12-13 2024-06-20 Evotec International Gmbh Protéines de liaison à l'antigène associées à l'interféron destinées à être utilisées pour le traitement ou la prévention d'une infection par le virus de la grippe
WO2024126293A1 (fr) * 2022-12-13 2024-06-20 Evotec International Gmbh Protéines de liaison à l'antigène associées à l'interféron destinées à être utilisées dans le traitement ou la prévention d'une infection par le virus respiratoire syncytial

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
RU2377254C2 (ru) * 2003-12-25 2009-12-27 Кирин Фарма Кабусики Кайся Мутанты анти-cd40 антитела
AU2008207898B2 (en) * 2007-01-23 2012-05-03 Xencor, Inc Optimized CD40 antibodies and methods of using the same
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
JP6738831B2 (ja) * 2015-05-04 2020-08-12 アポジェニックス アーゲー 単鎖ｃｄ４０受容体アゴニストタンパク質
HK1252675A1 (zh) * 2015-06-12 2019-05-31 Alector Llc 抗cd33抗体及其使用方法
MX2017016502A (es) * 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CA3016534A1 (fr) * 2016-03-04 2017-09-08 The Rockefeller University Anticorps anti-cd40 presentant une activite agoniste renforcee

Also Published As

Publication number Publication date
AU2019349874A1 (en) 2021-04-29
WO2020065409A3 (fr) 2020-05-07
JP2022503961A (ja) 2022-01-12
CA3114567A1 (fr) 2020-04-02
JP7626698B2 (ja) 2025-02-04
WO2020065409A2 (fr) 2020-04-02

Similar Documents

Publication Publication Date Title
WO2020065409A3 (fr) Molécules de liaison anti-cd40 ayant des domaines fc modifiés et leurs utilisations thérapeutiques
WO2016081746A3 (fr) Anticorps comprenant des régions constantes de chaîne lourde modifiées
MX2024004322A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
WO2018183520A8 (fr) Agents thérapeutiques et méthodes d'amélioration de réponses immunitaires dans un micro-environnement tumoral
EP4467648A3 (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
WO2009071696A3 (fr) Molécules d'anticorps humanisés spécifiques pour il-31
AU2018271872A1 (en) A protein binding NKG2D, CD16 and ROR1 or ROR2
MX2007015487A (es) Moleculas que son capaces de inhibir la union entre el factor de crecimiento de nervios y el receptor trka como analgesicos con efecto prolongado.
EP1998799B8 (fr) Anticorps humanisés dirigés contre l'antigène cd22 et leur utilisation à des fins thérapeutiques en oncologie, ainsi que dans le cadre de transplantations et de maladies auto-immunes
MX2020006508A (es) Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas.
WO2007047112A3 (fr) Anticorps anti-myostatine
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
EP3774921A4 (fr) Domaines variables d'anticorps ciblant les dll3, et leur utilisation
MX2019014375A (es) Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
EP4406550A3 (fr) Anticorps anti-cd40 à activité agoniste améliorée
EP2737907A3 (fr) Anticorps anti-ICOS et leur utilisation dans le traitement de l'oncologie, la transplantation et les maladies auto-immunes
MX2009009261A (es) Anticuerpos anti-ip-10 y metodos para su uso.
NO20083712L (no) Peptider som blokkerer bindingen av IGG til FCRN
MY159201A (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2009135861A3 (fr) Anticorps humanisés contre l'interféron-alpha humain
NZ748777A (en) Binding molecules specific for fcγriia and uses thereof
WO2008150530A3 (fr) Molécules de liaison de cripto
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
WO2017151971A3 (fr) Procédés se rapportant à des constructions fc génétiquement modifiées
BR112012013734A2 (pt) anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19867441

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2021517801

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3114567

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20217012243

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019349874

Country of ref document: AU

Date of ref document: 20190927

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019867441

Country of ref document: EP

Effective date: 20210428